Home » China’s Sinopharm Begins Phase 3 COVID-19 Vaccine Trial in United Arab Emirates
China’s Sinopharm Begins Phase 3 COVID-19 Vaccine Trial in United Arab Emirates
China-owned pharmaceutical company Sinopharm has begun a phase 3 clinical trial of its COVID-19 vaccine candidate in the United Arab Emirates.
The study will evaluate two formulations of the vaccine in 15,000 volunteers ages 18-60 and is expected to last for three to six months.
Sinopharm’s inactivated COVID-19 vaccine demonstrated a 100 percent immune response in phase 1 and 2 clinical trials.
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May